Drugs / all-trans retinoic acid (ATRA)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02751255 | Jul 2016 → Oct 2022 | plasma cell myeloma | Amsterdam UMC, location VUmc | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | all-trans retinoic acid (ATRA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02751255 ↗ |
| Known as | ATRA | “all-trans retinoic acid (ATRA)” NCT02751255 ↗ |
| Route | Oral | “ATRA will be administered twice daily as an oral formulation” NCT02751255 ↗ |
| Target | CD38 | “ATRA upregulates CD38 levels and downregulates CD55/CD59 levels on MM cells” NCT02751255 ↗ |
| Target | CD55 | “ATRA upregulates CD38 levels and downregulates CD55/CD59 levels on MM cells” NCT02751255 ↗ |
| Target | CD59 | “ATRA upregulates CD38 levels and downregulates CD55/CD59 levels on MM cells” NCT02751255 ↗ |